Clinical trial · Observational
A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epitope exploration | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Case
- interventionNames
- Diagnostic Test: Epitope exploration
- label
- Control
- interventionNames
- Diagnostic Test: Epitope exploration
Primary outcomes (1)
- measure
- Dominant gp42-IgG epitopes in cases
- timeFrame
- Baseline
- description
- Dominant gp42-IgG epitopes revealed by ELISA with non-competitive monoclonal humanized antibodies against gp42 will be compared between cases and controls.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Controls underwent physical examinations or primary NPC cases confirmed by pathology or cytology. * If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th. * If cases, Karnofsky score (KFS)≥70, estimated survival span\>12 months. * If cases, no disordered of major organs is found; blood test, liver, and kidney functions are basically normal. * If cases, at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1. Exclusion Criteria: * History of other malignant diseases. * History of severe systemic diseases or heart, lung, liver, or kidney disfunction. * History of severe neurological, metal, endocrine diseases. * History of HBV, HCV, HIV, TP, or TB infection. * If controls, physical examination reveals systemic diseases including malignant diseases. * If cases, incomplete blood and pathological sample data. * If cases, not receiving primary treatment in this facility. * Other individuals investigators find not suitable for the trial.
References
Publications (0)
Data not yet available